University of Iowa

Medical Cannabis Sleep Solution is Formulated with Minor Cannabinoids and Backed by Research At Bud & Mary’s, we’re deeply invested in understanding how cannabinoids interact with the brain and body, especially when it comes to improving individuals’ sleep quality.” — Lucas Nelson, Group President of Bud & Mary’s DES MOINES, IA, UNITED STATES, June 5, 2025 / EINPresswire.com / -- DES MOINES, Iowa (June 5, 2025) — Iowa medical cannabis patients can now access Bud & Mary’s NUO Sleep Tablets , a science-driven oral product that is the first of its kind in the state formulated with a blend of THC, CBD, and the minor cannabinoid CBN. Discreet, portable and precisely dosed, NUO Sleep Tablets are crafted to ease patients into a peaceful night and help them wake feeling refreshed. Scored for titrating doses, NUO Sleep Tablets serve medical cannabis patients seeking a smoke-free non-combustible, orally administered format that helps set the mood for sleep. The tablets -- free from sugar, preservatives, dyes, alcohols and artificial ingredients -- demonstrate Bud & Mary’s ongoing commitment to creating trusted, research -backed cannabis therapies. “At Bud & Mary’s, we’re deeply invested in understanding how cannabinoids interact with the brain and body, especially when it comes to improving individuals’ sleep quality” said Lucas Nelson, Group President of Bud & Mary’s. “NUO Sleep Tablets reflect that commitment, combining precise dosing with emerging research on minor cannabinoids such as CBN. It is the next step in our work to offer Iowa patients reliable, non-combustible therapies that are grounded in science and tailored for real-world needs.” Bud & Mary’s is one of the only U.S. cannabis license holders with a DEA Schedule 1 researcher license, enabling federally authorized cannabis research. With an ISO 17025-accredited analytical laboratory, cGMP/GACP-certified production, and multiple active clinical studies, the company sets a national standard for cannabis innovation, scientific rigor, and product safety. “Sleep is one of our most fundamental biological needs, yet so many people struggle to get consistent, uninterrupted sleep,” said Dr. Duncan Mackie, Director of Pharmacology & Experimental Therapeutics at Bud & Mary’s. “Research has shown that disturbed or insufficient sleep can affect mood, cognitive performance, and overall physical health. Now, NUO Sleep Tablets offer Iowa patients a reliable, science-backed option to assist them in obtaining a peaceful, uninterrupted night’s sleep.” As part of Bud & Mary’s dedication to researching how cannabis-based therapeutics can transform lives, the company is currently conducting a sleep-focused clinical trial with the University of Iowa, studying the effects of a patented cannabinoid-based therapeutic intradermal gel designed to improve sleep among individuals aged 50 or older with diagnosed sleep disturbances. Iowa medical cannabis patients with valid prescriptions can find NUO Sleep Tablets in licensed dispensaries across the state in 10-count and 30-count bottles. Patients can locate Iowa dispensaries that offer NUO Sleep Tablets in the store locator at this link. Product images are available at this link. Iowans seeking more information on obtaining a medical cannabis card can visit BudMary.com/IA/GetACard. For more information or to schedule an interview, please contact Irene Ancheta at 310-804-5493 or irene@themaverickpr.com. Bud & Mary’s: Crafted for You, Powered by Science. At Bud & Mary’s, we take a science-driven approach to crafting premium cannabis products designed for every individual. From our best-selling BATCH vape cartridges to our innovative water-soluble TheMyx powder and wellness-focused brands Become and NUO, every product is developed with care, precision, and an unwavering commitment to quality. Locally grown and rigorously tested, Bud & Mary’s products meet the highest standards of safety, consistency, and excellence. As we’ve pushed boundaries of cannabis innovation and expanded our offerings into Colorado, Michigan, Iowa, and Missouri, we’ve remained true to our family-owned and operated roots and people-focused values. For more information, visit BudMary.com. Continue the conversation on Facebook, Instagram, X, LinkedIn and TikTok. # # # Irene Ancheta Maverick Public Relations +1 310-804-5493 email us here Visit us on social media: LinkedIn Instagram Facebook TikTok X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

iStock, Jorm Sangsorn In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups offered solutions to ease the impacts if the plan must go ahead. Despite billions being committed to reshoring pharma manufacturing in the face of tariff threats from President Donald Trump, industry does not seem prepared to entirely forgo foreign operations. In particular, rare disease biotechs and those developing complex modalities like cell and gene therapies have urged the Trump administration to provide exemptions to pending pharma tariffs. The pleas come in the form of comments filed over the past few weeks on the government’s Section 232 investigation being conducted to determine if tariffs can be levied against pharma companies as a matter of national security. “With 95% of the more than 10,000 known rare diseases still lacking an FDA-approved therapy, it is in the interest of the public health to preserve incentives that sustain this innovation ecosystem for rare diseases,” BioMarin wrote in its seven-page letter. The company has a handful of approved gene therapies such as Roctavian for hemophilia A as well as new medicines for diseases that have long lacked options, but has struggled to break even. BioMarin’s is one of hundreds of comments posted last week via the Federal Register. Combing through them reveals the broad issues that companies and industry groups have with the proposed import taxes. The Alliance for Regenerative Medicine (ARM) said that tariffs could undermine and slow access to cell and gene therapies for U.S. patients. If tariffs are put into place, ARM urged the administration to do so in a phased approach that would provide time for companies to reshore production. Small volume imports could also be exempted, the group said. ARM explained that regenerative medicines are sometimes produced for just a handful of patients in a year and demand can be highly variable. But when they are needed, the situation is often time-critical, meaning companies require certainty that they can access the needed ingredients, which often come from outside the U.S. “To ensure patient access, manufacturers must have confidence that they can secure ingredients from the widest possible set of reliable sources, at a predictable cost,” the group said. ARM asserted that even though the patient population for cell and gene therapies is small, losing access to them would be devastating. “Disrupting access to these therapies will cut off some of the most vulnerable and complex patients in our healthcare system from life-changing treatment,” the group’s comment read. The Rare Disease Company Coalition similarly advocated for its patient community by requesting that orphan drugs and their components be exempted from tariffs. The group is run by executives from rare disease companies including Fulcrum Therapeutics, AstraZeneca’s rare disease subsidiary Alexion, argenx, Travere Therapeutics, Sarepta Therapeutics and Inozyme Pharma. “Efforts to rapidly reshore the entire supply chain for orphan drugs, including those in development and those already approved, would be economically prohibitive,” RDCC wrote. “Orphan drug manufacturers lack economies of scale and often depend on highly specialized overseas partners for producing and packaging the final dosage form.” BioMarin said it has recently become profitable after years of reinvesting the bulk of its revenue back into R&D. This was possible thanks to the Orphan Drug Act, which was enacted by Congress with the goal of ensuring that all trade policies support incentives for orphan drug development. The company requested that orphan drugs be excluded from potential tariffs. “Tariffs on these finished products and critical inputs would have an immediate and disproportionate effect on the availability and affordability of orphan drugs,” BioMarin wrote. “Increased costs and supply disruptions could delay treatment development, constrain manufacturing capacity, and threaten timely access to life-saving medicines for patients who have no therapeutic alternatives.” Complex Cancer Drugs Perspective Therapeutics, a biotech developing radiopharmaceuticals, also asked for leniency considering the highly specialized manufacturing process for its complex radiation therapeutics. While some of the comment from CEO Thjis Spoor was blacked out, he asked the Trump administration to defer tariffs on the specialized equipment needed to manufacture its radiopharmaceutical cancer therapies. The company already conducts most of its work in the U.S., having spun out of research at the University of Iowa and operating two stateside manufacturing sites. Japanese biopharma Daiichi Sankyo touted the success of its AstraZeneca-partnered cancer antibody drug conjugate (ADC) Enhertu, and follow-up drug Datroway, as success stories that have benefitted cancer patients in the U.S. But as with radiopharmaceuticals, ADCs are complex to manufacture, with the potential for batch-to-batch variations. Enhertu is manufactured at facilities in the U.S., Japan and Europe, then packaged in Ohio before warehousing and distribution from Tennessee. “Moving the overseas manufacturing steps to the U.S. would require significant overhaul of the company’s operations and substantial financial costs,” Daiichi explained. The company is already moving some additional processes to the U.S. in the coming years, but the second step—production of the conjugated product—is done overseas and would be hit by tariffs if imposed. “The application of tariffs to Enhertu and Daiichi Sankyo’s other medicines risks real consequences on the company’s ability to meet its goals for significant investment in the future of new treatments for patients and planned manufacturing capacity in the U.S.,” Daiichi wrote.

1 Columbia University Medical Center New York, New York 2 Brigham and Women's Hospital Boston, Massachusetts 8 University of Kansas Medical Center Kansas City, Kansas 10 University of Pennsylvania Philadelphia, Pennsylvania 11 University of Virginia Health System Charlottesville, Virginia 13 Vanderbilt University Medical Center Nashville, Tennessee 14 Indiana University Medical Center Indianapolis, Indiana 17 Mayo Clinic Rochester, Minnesota 18 National Institutes of Health Bethesda, Maryland 20 Stanford University School of Medicine Stanford, California 25 The State University of New York at Buffalo Buffalo, New York 28 VA San Diego Healthcare System San Diego, California 32 Massachusetts General Hospital Boston, Massachusetts 33 University of Maryland Medical System Baltimore, Maryland 36 University of Southern California Los Angeles, California 37 Temple University Philadelphia, Pennsylvania 38 Ernest Orlando Lawrence Berkeley National Laboratory Berkeley, California 40 Emory University Atlanta, Georgia 41 University of California, Los Angeles - UCLA Los Angeles, California 42 Johns Hopkins Medical Institutions Baltimore, Maryland 44 The University of Texas Southwestern Medical Center Dallas, Texas 45 The University of Michigan Medical School Ann Arbor, Michigan 46 University of Texas Medical Branch Galveston, Texas 47 University of California, San Diego San Diego, California 48 The University of Iowa Iowa City, Iowa 51 The Methodist Hospital DBA (doing business as) "Houston Methodist" Houston, Texas 56 University of Texas Health Science Center at San Antonio San Antonio, Texas 59 Loma Linda University Medical Center Loma Linda, California 62 VA Greater Los Angeles Healthcare System Los Angeles, California 63 University of Alabama at Birmingham Birmingham, Alabama 70 Thomas Jefferson University Philadelphia, Pennsylvania 71 University of California, San Francisco San Francisco, California 78 University of Utah Salt Lake City, Utah 91 University of Wisconsin School of Medicine and Public Health Madison, Wisconsin 92 University of California - Davis Medical Center Sacramento, California 101 NYU Langone Health New York, New York 103 North Shore University Hospital Manhasset, New York 105 Memorial Sloan-Kettering Cancer Center New York, New York 122 Washington University School of Medicine St. Louis, Missouri 125 Corewell Health (formally Beaumont Health) Royal Oak, Michigan 135 University of Colorado Anschutz Medical Campus Aurora, Colorado 145 University of Minnesota Minneapolis, Minnesota 160 State University of New York at Stony Brook Stony Brook, New York 161 University of Pittsburgh Pittsburgh, Pennsylvania 170 University of Tennessee Medical Center Knoxville, Tennessee 175 Wake Forest University Health Sciences Winston Salem, North Carolina 179 Louisiana State University Health Sciences Center in Shreveport Shreveport, Louisiana 184 The University of Washington Seattle, Washington 185 West Virginia University Hospitals Inc. Morgantown, West Virginia 186 Karmanos Cancer Institute (KCI) Detroit, Michigan 201 Banner University Medical Center - Phoenix (BUMCP)/ Banner Alzheimer's Institute (BAI) Phoenix, Arizona 202 University of North Carolina at Chapel Hill Chapel Hill, North Carolina 203 Tennessee Valley Healthcare System (Nashville VA Medical Center) Nashville, Tennessee 206 Yale University New Haven, Connecticut 207 Medical College of Wisconsin Milwaukee, Wisconsin 208 BAMF (Bold Advanced Medical Future) Health Grand Rapids, Michigan Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.